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Abstract 
Upper gastrointestinal bleeding (UGIB) remains a common dis-
ease affecting 100 to 170 per 100 000 adults per year and causing
thereby a significant burden to healthcare resources. Despite the
improvements in the management of this disorder, the associated
mortality ranges from 5 to 14%.
Since the general management of UGIB is not uniform, the main
objective of this work is to provide guidelines for the care of adults
and children presenting with bleeding caused by gastro-duodenal
ulcer or variceal rupture.
Methods : In the absence of evidence-based recommendations,
these guidelines were proposed after expert opinions reconciliation
and graded accordingly. They are based on the published literature
up to September 2010 and graded according to the class of
 evidence. 
Results : The current guidelines for the management of UGIB
include recommendations for the diagnostic process, general sup-
portive care, pharmacological therapy aiming at bleeding control,
specific and endoscopic treatment of acute bleeding and follow-up
for both gastro-duodenal ulcers and portal hypertension-induced
bleeding. (Acta gastro enterol. belg., 2011, 74, 45-66).




Upper gastrointestinal bleeding (UGIB) is a common
disorder with an important burden on healthcare
resources. Its incidence in Europe is around
1-2/1000 inhabitants and UGIB is still associated with a
mortality rate of 5-14%. Gastro-duodenal ulcers and
other erosive lesions account for most of the cases
(80%). Portal hypertension represents about 10 to 15%
of UGIB episodes with 75% related to oesophageal
variceal bleeding and 20% to gastric variceal bleed-
ing (1). Upper gastrointestinal endoscopy is the standard
of care in the diagnosis and in the first-line treatment of
UGIB. It reduces recurrent bleeding, need for surgery
and mortality (2). However, management of UGIB
involves many other aspects of care including resuscita-
tion, transfusion, medical therapy, radiological interven-
tions or surgery. 
There is considerable variability in the management
of these different aspects of the care of UGIB between
different European countries and between hospitals with-
in the same country (3,4). In addition, various specialists
including general practitioners, emergency physicians,
gastroenterologists and hepatologists, intensivists, radio -
logists and surgeons may be involved in the management
of UGIB augmenting the potential for variability and a
less than optimal care. We therefore considered that
interdisciplinary guidelines for the management of
UGIB based on current standards for Evidence Based
Medicine (EBM) would provide an opportunity for
 clinicians to improve the management of their patients
with UGIB. We do not believe that guidelines are
 mandatory tenets appropriate for all patients. Clinical
guidelines should constitute a canon or principle tailored
to the individual patient (5). In addition, EBM might
 provide quality indicators for the assessment of care to
bleeding patients at a local, national or international level
as recently published (6).
Processes and methods to define the Belgian guidelines
The current guidelines have been based on the published
literature up to September 2010 and graded according to
the class of evidence (Table 1). Where EBM recommen-
dations were lacking, guidelines were proposed on
 reconciled expert opinions and commented in the
 manuscript. 
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Resuscitation
Any patient with tachycardia above 100/min or a sys-
tolic blood pressure < 100 mmHg or an increased lactate
should be considered for volume replacement.
Analogous to patients presenting with severe sepsis or
septic shock, the target for volume loading is a mean
arterial blood pressure (MAP) > 65 mmHg and/or a sys-
tolic blood pressure > 100 mmHg (5-D) (7). In patients
with a tentative diagnosis of non-variceal bleeding
2 litres of crystalloids followed by colloids constitute a
reasonable initial approach. In patients with a strong sus-
picion of variceal bleeding due to liver cirrhosis, albumin
5% is deemed to be the preferred volume expander (5-
D). Once hemodynamic targets have been reached and in
the absence of contra-indications due to cardiac or renal
co-morbidity, volume replacement at 30 mL/kg per 24 h
is appropriate. 
In patients with persistent hypotension (MAP
< 65 mmHg) for more than 30 minutes in spite of vigor-
ous fluid loading, temporary normalization of MAP with
a vasopressor can minimize or prevent subsequent organ
dysfunction. The vasopressor of choice in this setting is
noradrenalin (5-D). In case of variceal bleeding,
 terlipressin can be a valid alternative (5-D).
Blood transfusion
Based on a large randomised trial in critically ill patients,
transfusion of packed red blood cells above 8 g/dL con-
fers no benefit for outcome. In patients with a history of
coronary or cerebrovascular diseases the transfusion trig-
ger is higher and set at 9-10 g/dL (1-B).
Intubation and sedation
It is well known that endoscopy performed in optimal
conditions is associated with a better control of bleeding,
shorter intensive care unit (ICU) and hospital stay (1b-
A). Unfortunately, there is a complete absence of
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General management of UGIB before endoscopy
Establishing a tentative diagnosis
Endoscopy is the gold standard for diagnosing the
cause of UGIB. Until the time of endoscopic investiga-
tion, the history of the patient (if necessary and if avail-
able through next of kin) and the clinical presentation
will help to establish a tentative diagnosis. A tentative
diagnosis of variceal bleeding will lead to a different
management strategy than for non-variceal bleeding (5-
D). Any physician having the initial contact with a
patient presenting with signs of UGIB should certainly
attempt to answer at least the following four questions at
the very beginning of the approach to the patient :
1) Does the patient have a history of aortic aneurysm
with or without surgery ? If the answer is yes and the
patient is hemodynamically stable, the initial investi-
gation should not be endoscopy but contrast CT scan.
If the patient is unstable, prompt surgical expert
advice must be sought for with the option of immedi-
ate surgery because bleeding from an aorto-enteric
fistula is highly probable (5-D). 
2) Is the history or clinical examination suggestive of
bleeding related to portal hypertension ? If the
answer is yes, vasoactive medication must be started
immediately (1-A).
3) Does the clinical examination suggest impaired vital
organ function (tachycardia, hypotension, tachypnea,
altered consciousness, cold extremities) ? If the
answer is yes, the patient should be placed in a mon-
itored environment immediately, contact should be
established with an emergency physician or intensive
care specialist and the initial lab investigation should
include lactate measurement and blood typing and
cross-matching (5-D). 
4) Is the patient taking anticoagulant or antiplatelet
 therapy ? Vide infra.
Table 1. — Level of evidence and grade of recommendations
RCT : randomized controlled clinical trial.
Level of Evidence Grading Criteria Grade of Recommendation
1a Systematic review of RCT’s including meta-analysis A
1b Individual RCT with narrow confidence interval A
1c All or none RCT’s B
2a Systematic review of cohort studies B
2b Individual cohort study and low quality RCT B
2c Outcome research study C
3a Systematic review of case-control studies C
3b Individual case-control studies C
4 Case series, poor quality cohort and case control studies C
5 Expert opinion D
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 randomized trials and a paucity of trials in general that
have been looking at whether or not prophylactic intuba-
tion might improve outcome in patients with UGIB (8-
10). The existing literature is exclusively based on retro-
spective studies and the data suggest that prophylactic
intubation in both variceal and non-variceal bleeding
does not change the incidence of cardiovascular events,
aspiration pneumonia or mortality (4-C) (8-11).
However, common sense supports that endotracheal
intubation should be performed before endoscopy in
patients with ongoing hematemesis, hemodynamic insta-
bility in spite of volume loading, agitation with the
absence of co-operation or Glasgow Coma Scale (GCS)
< 8 (5-D) (12). An additional indication for intubation is
the patient that becomes agitated or suffers from renewed
hematemesis during the endoscopic procedure (5-D).
What is a high-risk patient ? Who should be transferred
to an ICU ?
Currently, 2 scores are widely used for assessing
patient’s risk of adverse outcome (need for transfusion,
rebleeding or death). The Rockall score is the oldest pub-
lished and integrates endoscopic variables to predict
the risk of mortality or of recurrent bleeding
(Table 2) (13,14).
However, until endoscopy several decisions will have
to be made which depend very much on whether or not
the patient has a high risk profile. A modified admission
Rockall score was developed without including endo-
scopic variables, but it is less powerful as predictor.
More recently, the Glasgow Blatchford bleeding score
(GBS) was described which includes simple admission
variables (15) (Table 3). The GBS has been validated in
different countries and is more powerful than both the
admission and full Rockall scores in predicting the need
for transfusions, endoscopic treatment, surgery or
death (16). Moreover, it allows to safely select patients
with very low risk (GBS = 0), to be managed as outpa-
tients (17). A patient should be classified as high risk in
the presence of a GBS ≥ 8 (2-B). These patients should
be transferred to an ICU as soon as possible. Other
patients that may clearly benefit from ICU care are those
with persistent bleeding in spite of endoscopic therapy
and those who have witnessed massive aspiration of
blood (5-D).
Vasoactive medication before endoscopy 
Vasoactive medication for suspected variceal bleeding
(oesophageal and gastric varices)
The aim of using vasoactive drugs is to cause splanch-
nic vasoconstriction, thereby decreasing portal pressure
and thus stopping or reducing bleeding from varices.
Vasoactive medications in the setting of variceal bleed-
ing are clearly indicated as they stop the bleeding in 75-
80% of patients and because they reduce the risk for
recurrent bleeding (1a-A). Vasoactive drugs should be
started as soon as possible before diagnostic endoscopy,
when variceal hemorrhage is suspected. This can be done
during transfer to or at arrival at the hospital (1b-A) (18-
20). Although optimal duration of the vasoactive drug
treatment is not well established, most centres maintain
the treatment for 5 days, because this is the period during
which the risk of rebleeding is the highest. The recent
Baveno V guidelines of May 2010 state that the vasoac-
tive therapy should be continued for 5 days (5-D) (20) ;
while the Baveno IV guidelines stated 2 to 5 days (1a-
A) (18,20,21).
The choice of vasoactive drug should be based on
local availability and efficacy. In the US, only octreotide
is available, however evidence for using octreotide in
variceal bleeding is very low because of tachyphylax-
is (12). In Belgium and Europe octreotide, somatostatin,
vapreotide, vasopressin and terlipressin are available.
Vasopressin has too many side effects and is not used
anymore in variceal bleeding. Terlipressin is a potent
splanchnic vasoconstrictor with fewer side effects than
vasopressin. Somatostatin has also few side effects and
can also be used adjunctively to endoscopic therapy. 
Either terlipressin or somatostatin should be used in
combination with endoscopic treatment, because
 combination therapy increases the control of bleeding by
another 12% and lowers the risk for rebleeding by
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Table 2. — Rockall score (13,14)
The Rockall risk scoring system identifies patients at risk of adverse outcome following acute UGIB. The total score is calculated by simple addi-
tion of the scores for the different variables. A score < 3 carries a good prognosis ; a total score > 8 carries a high mortality risk.
Variable Score 0 Score 1 Score 2 Score 3
Age (years) < 60 60-79 > 80
Shock No shock Heart rate > 100/min Systolic blood pressure < 100 mmHg
Comorbidity No major Chronic heart failure, ischemic heart dis-
ease, major comorbidity
Renal failure, liver failure,
metastatic cancer
Diagnosis Mallory Weiss All other diagnoses GI malignancy
Evidence of bleeding None Blood, adherent clot, spurting vessel
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bolus can be repeated up to 3 times within 1 hour. In
patients with active bleeding at the time of endoscopy,
the infusion regimen can be increased up to 12 mg/24 h
(= 500 µg/h). Side effects are rare and there are no major
contraindications (21,25,28).
When comparing somatostatin with terlipressin, they
have the same bleeding control, risk for rebleeding and
mortality rate are found to be similar (21). 
Vasoactive medications for non-variceal bleeding
In 1997 a meta-analysis of 14 trials that included
1829 patients treated with somatostatin or octreotide
compared with histamine-2-receptor antagonists or
placebo, concluded that somatostatin may reduce the risk
for continued bleeding from acutely bleeding ulcer dis-
ease. The authors suggested that large clinical trials were
needed in patients carefully stratified by source, severity
and type of bleeding were needed. In 2000, a prospective
study with 48 patients showed that somatostatin was no
more effective than ranitidine. No further evidence has
been published in peer-reviewed Journals since then sup-
porting the routine use of somatostatin in peptic upper GI
bleeding. Furthermore no study with the current gold
standard of acid suppression (i.e. proton pump inhibitors
- PPIs) has been conducted in this setting (29,30).
Therefore, there is insufficient evidence to recom-
mend somatostatin or any other vasoactive medication in
the routine treatment of suspected non-variceal UGIB
(2b-C).
PPI before endoscopy
PPI in non-variceal bleeding 
In patients with overt signs of UGIB but without per-
sistent hypovolemic shock, an IV bolus of 80 mg
omeprazole, followed by 8 mg/hour for 72 hours, admin-
istered after hemodynamic stabilization and before
endoscopy, was reported to be effective in accelerating
the resolution of signs of bleeding from ulcers and in
reducing the need for therapeutic endoscopy. A recent
Cochrane meta-analysis confirmed these findings (31)
(1a-A). Another 2010 meta-analysis showed that there is
no evidence that continuous high dose PPI (8 mg/h for
72 h) has a better outcome than fractionated low dose (2
× 40 mg/d) PPI for active ulcer bleeding (32). Therefore
the panel recommends using 2 × 40 mg/d, the first dose
being given before endoscopy as soon as a tentative
diagnosis of non-PHT related bleeding is made (5-D). In
low risk patients tolerating oral medication, the strategy
of giving oral PPI before and after endoscopy, with endo-
scopic hemostasis for those with no major stigmata of
recent hemorrhage, is likely to be the most cost-effec-
tive (31-38).
PPI in variceal bleeding
There is no evidence for the use of PPI in the setting
of active variceal bleeding or after endoscopic therapy
(Baveno V) (20).
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 another 12% (20,22,23). There are no RCT’s comparing
both drugs combined with endoscopic therapy. However,
terlipressin versus placebo has shown improved survival
in one small RCT and in a meta-analysis (21,24-26).
Terlipressin improves the rate of bleeding control
(within 48 h : 75-80% ; within 5 days 67%) and survival.
The dose of terlipressin is an initial intravenous (IV)
bolus : < 50 kg = 1 mg ; 50-70 kg = 1.5 mg ; > 70 kg =
2 mg followed by an IV bolus of 1-2 mg every 4 h for
48 h, followed by 1 mg every 4 h till day 5.
Contraindications for the use of terlipressin include coro-
nary insufficiency, peripheral vascular disease, pregnan-
cy, heart rhythm disease, severe bronchial asthma,
uncontrolled arterial hypertension and epilepsy. The risk
for side effects appears to be less when given in contin-
uous IV infusion (e.g. 4-6 mg/24 h) at least for hepatore-
nal syndrome (27). 
Somatostatin treatment starts with a continuous IV
infusion of 6 mg/24 h (= 250 µg/h) immediately fol-
lowed by a bolus of 250 µg IV within 5 minutes. The
Table 3. — The Glasgow-Blatchford bleeding score
(GBS) (15)
Low risk if Score is “0”
High risk is any score > 0 needing medical intervention, transfusion,
endoscopy or surgery
ICU admission is indicated if GBS ≥ 8
Score is "0"only if all the following are present :
1. Hemoglobin level > 12.9 g/dL (men) or > 11.9 g/dL (women)
2. Systolic blood pressure > 109 mm Hg
3. Pulse < 100/minute
4. Blood urea nitrogen level < 39 mg/dL
5. No melena or syncope
6. No past or present liver disease or heart failure.
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Antifibrinolytic medication
Seven double-blind randomized trials on tranexamic
acid vs. placebo have been published to date, most dating
from the seventies and eighties. Only one of these trials
includes endoscopic treatments and proton pump
inhibitors, i.e. the present standard of care. The trial did
not find any significant effect of tranexamic acid on clin-
ical outcome measures. There is no indication for the use
of antifibrinolytics in the treatment of variceal or non-
variceal UGIB (1a-A) (39).
Antimicrobial prophylaxis
In the setting of UGIB, only patients with known or
suspected cirrhosis should receive antimicrobial prophy-
laxis. The initial work-up of these patients should
include an active search for infection (blood, ascites and
urine cultures) (1a-A). Proposed first line antibiotics are
amoxicillin-clavulanic acid, third generation
cephalosporins or quinolones according to local resist-
ance patterns. In patients receiving maintenance therapy
with quinolones as prophylaxis for spontaneous bacteri-
al peritonitis, third generation cephalosporins are the first
choice. Prophylactic antibiotherapy should not be con-
tinued for more than 7 days (18,20). 
Coagulation disorders, should anti-Vit K medication
and/or anti-platelet medication be discontinued in bleed-
ing ?
Antiplatelet drugs and anticoagulants are commonly
used for the treatment and the prophylaxis in vascular
diseases. Endoscopic therapy in patients with an acute
bleeding while using antiplatelet agents (acetyl salicylic
acid, clopidogrel, ticlopidine, dual antiplatelet therapy,
glycoprotein IIb/IIIa inhibitors…) is both warranted and
safe (40,41). Stopping these agents prior to endoscopy
may pose unnecessary atherothrombotic risks and there-
fore needs careful evaluation. On the other side, in
patients with clinically significant UGIB, continued
administration of antiplatelet drugs or anticoagulants is
known to be associated with a high risk of persistent
bleeding. 
There is no clear recommendation about either how
long these drugs should be discontinued, or whether the
reversal of anticoagulation should be partial or complete.
The individual decision must be based on the balance
between the risk of thromboembolism and that of contin-
uing bleeding. The same balance should be considered to
determine the timing of reinstitution of these treat-
ments (40-44).
The American Society of Gastroenterology (ASGE)
proposed a classification of high or low risk for throm-
boembolic event, thereby providing a tool to appreciate
this balance (Table 4) (40,41).
In non-cirrhotic patients there is good evidence that
anti-Vitamin K therapy (AVK therapy), targeted at an
INR of 2.5 (range 2-3) is associated with a lower risk of
bleeding than therapy targeted at an INR > 3. In patients
with UGIB correction of the INR < 2.5 is advised (4-C).
Correction to an INR of 1.5 to 2.5 allows successful
endoscopic diagnosis and therapy (45).
For patients with serious bleeding and elevated INR
(regardless of the magnitude of the elevation), the
American College of Chest Physicians recommends to
hold the AVK and to give 10 mg vitamin K by slow IV
infusion. A supplement of fresh frozen plasma (FFP) or
prothrombin complex concentrate (PCC) is also
 proposed depending on the urgency of the situation but
certainly in a life threatening bleeding (2C) (41). 
The timing for resumption of anticoagulation should
be individualized taking into account the risk for throm-
boembolic event (see Table 4). In patients with high risk
for thromboembolic event and for rebleeding, the use of
unfractionated heparin (UFH) could be considered due to
the advantage of a short half-life. 
For non-cirrhotic patients using antiplatelets drugs,
there are no clear recommendations. Some suggest with-
holding these medications until hemostasis is achieved,
however, due to the long half life of clopidrogel (7 days),
stopping the drug will not have any impact on the short
term, so endoscopy and treatment are safe under
antiplatelet therapy (5-D). In the absence of randomized
controlled trials (RCT’s) the panel suggests that platelets
transfusion could be considered if the platelet count is
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Table 4. — Condition risk for thromboembolic events (ASGE standards of practice committee for the management
of antithrombotic agents for endoscopic procedures) (40)
Higher-risk condition Low-risk condition
Atrial fibrillation associated with valvular heart disease, prosthetic valves, active
congestive heart failure, left ventricular ejection fraction < 35%, a history of a
thromboembolic event, hypertension, diabetes mellitus, or age > 75 y
Uncomplicated or paroxysmal nonvalvular atrial fibrillation
Mechanical valve in the mitral position Bioprosthetic valve
Mechanical valve in any position and previous thromboembolic event Mechanical valve in the aortic position
Recently (< 1 y) placed coronary stent Deep vein thrombosis
Acute coronary syndrome
Non-stented percutaneous coronary intervention after myocardial infarction
08-colle_Opmaak 1  26/01/11  13:46  Pagina 49
50 I. Colle et al.
(80%) but rebleeding after balloon deflation is high
(50%). The complication rate (aspiration, migration,
necrosis and perforation of oesophagus) is high and asso-
ciated with high mortality. The gastric balloon should be
deflated within 24 h to avoid necrosis of the stomach (in
case of simultaneous inflation of an oesophageal balloon
this one should be deflated every 4 hours). 
Linton tamponade (600 mL) can be used for
oesophageal and gastric varices (52). Sengstaken
Blakemore tamponade can only be used for oesophageal
varices (5-D). 
Recently a RCT showed that a covered oesophageal
stent can be placed for oesophageal varices, however this
is not recommended yet and should be confirmed in
other studies (12,20,21,53).
Endoscopic and other specific treatment modal-
ities for acute UGIB 
Optimal timing for endoscopy ? 
The optimal timing for endoscopy for non-PHT relat-
ed bleeding is within the 24 h of patient’s presentation
(1a ;A) (54). This allows for safe and prompt discharge
of patients classified as low risk, it improves patient out-
comes for high risk patients and reduces the use of
resources for patients at low or high risk. No evidence
exists for any clinical benefit of performing endoscopy
within 12 hours of presentation (reduction of rebleeding
rate or survival improvement) as this may lead to
increased use of endoscopic therapy, which may not be
necessary. This correlates to studies showing that
 performing emergency endoscopy in bad conditions
(without adequate human and material resources) is
associated with increased recurrent bleeding, need for
surgery and hospital stay (2b-B) (55). Besides this statis-
tical evidence, each case should indeed be individually
discussed, according to patient’s clinical situation and
maybe the GBS, as suggested before. 
If a variceal bleeding is suspected, endoscopy should
be performed as soon as possible but within 12 hours (5-
D) (18-20).
Hemodynamically unstable and high risk patients
should be transferred to ICU for conditioning and
 performing endoscopy, after intubation, in proper and
safe conditions.
Endoscopic treatment for non-variceal bleeding (Fig. 1)
Ulcers
Endoscopic treatment should be performed at the time
of diagnosis by an experienced endoscopist. Lesions that
are actively bleeding (Forrest Ia, b) and non-bleeding
visible vessels (Forrest IIa) should be treated endoscopi-
cally. Clots (Forrest IIb) should be removed by washing,
using a basket, snare or a cap (50) until the ulcer base is
visible for adequate treatment of the underlying ves-
sel (56,57,58) as the risk of rebleeding after endoscopic
treatment from a Forrest IIb ulcer is the same as for a
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lower than 30,000/µL in case of ongoing bleeding (5-
D) (40,44). The timing for resumption of antiplatelet
medication should be individualized taking into account
the risk for thromboembolic event (Table 4).
In cirrhotic patients, PT/INR is not a reliable indicator
of the coagulation status (Baveno V). On the basis of
currently available data, in these patients no definite rec-
ommendations can be made regarding management of
coagulopathy and thrombocytopenia (5-D) (18,20).
There is certainly no evidence for administration of
coagulation factors prior to endoscopy (5-D). Over-
transfusion with fresh frozen plasma (FFP) and platelets
cause an increase in portal pressure and may be associat-
ed with sustained bleeding (2b-B). In the absence of
RCT’s the panel suggests that platelets transfusion could
be considered if the platelet count is lower than
30,000/µL in case of ongoing bleeding (5-D). 
In the patient suffering from an acute coronary syn-
drome or recently having had placed a vascular stent, no
strong recommendations concerning antiplatelet drugs
can be made. A cardiologist should always be consulted
before stopping any antiplatelet agent, but drugs must be
continued in many cases (5-D).
Stomach cleansing before endoscopy
In the case of UGIB, a clean stomach or duodenum
during endoscopy is highly desirable. Naso-gastric
lavage is associated with complications and fails to be
efficient in half of the cases. A recent pharmacologic
method for cleansing the stomach has gained a 1a-A evi-
dence for its use before endoscopy after demonstration
of effectiveness (46-48) and cost / effectiveness (49) : the
IV administration of 250 mg erythromycin over 5 min,
20 min before endoscopy, dramatically increases the rate
of empty stomach, decreases the time of endoscopy and
the need for a second look. In this setting erythromycin
acts as a motilin agonist which induces potent gastric
contractions and evacuation of gastric blood clots.
In case of failure to clean the stomach, large operative
channel endoscopes or other tricks may be used like an
attachable distal cap that can facilitate the removal of
blood clots during endoscopic treatment (50).
Feeding and nasogastric tube
Although there are no studies, there are probably no
contra-indications to place a nasogastric tube after band
ligation or treatment of non-PHT related bleeding unless
other recommendation of the endoscopist. Oral feeding
can start when the patient is hemodynamically stable and
conscious (5-D).
When is tamponade indicated ?
Balloon tamponade is indicated for uncontrolled
bleeding from oesophageal/gastric varices for which a
definitive therapy is planned within 24 h (1-B) (51).
Balloon tamponade is effective in bleeding control
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Forrest IIa. Ulcers with a clean or black base do not need
endoscopic treatment (1a-A). The Forrest classification
is described in Table 5. 
Hemostasis can be performed using different inde-
pendent or combined methods.
a. Injection therapy with saline is widely applica-
ble, easy, inexpensive and can be used when front view
of the bleeding point cannot be maintained. Addition of
epinephrine (1:10,000 dilution) or a sclerosant offers no
advantage (59). Injection therapy should only be
 considered as a temporary measure because its effect is
only transient. It might allow clearing the endoscopic
field (60,56,61,62) (1a-A). This method is not to be
 considered as a definite treatment but as an adjunct to
more efficient and long-lasting hemostatic procedures.
b. Thermal coagulation and mechanical clipping
are more effective and sustained than injection therapy
alone in terms of bleeding control, rebleeding and need
for surgery (61,62).
Vascular ectasia
Argon Plasma Coagulation (APC) is useful for the treat-
ment of a vascular ectasia (63).
Acta Gastro-Enterologica Belgica, Vol. LXXIV, January-March 2011
Abbreviations : GBS : Glasgow-Blatchford bleeding score.
Fig. 1. — Algorithm for non-variceal bleeding
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surgery (OR 0,56 CI : 0,45-0,70) but not mortality. A
beneficial impact on mortality was only found in the sub-
group of patients with active bleeding or non bleeding
visible vessel who received haemostatic therapy and
high dose IV PPIs for 72h (OR 0,57 CI 0,34-0,96).
Lower doses of PPIs either IV or oral had no impact on
mortality in this subgroup. As far as costs are considered
for this strategy, high-dose IV PPI for high risk patients
after therapeutic endoscopy appear more effective and
less costly in Europe (68). However, the question of
lower IV PPIs dose is still open (32).
Failure to control non-variceal bleeding : when should
embolisation or surgery be considered ?
In patients in whom non-variceal bleeding cannot be
controlled with a second endoscopic attempt, angio-
graphic embolisation or surgery becomes the next thera-
peutic option. Where available, arteriography is an alter-
native option to surgery. This procedure can often obvi-
ate the need for surgery and is particularly useful for
those unfit for surgery. Visualization of the bleeding ves-
sel requires active bleeding at the time of arteriography
at a rate of approximately 2 ml/min. Even though bleed-
ing rate is not constant, angiography has a high probabil-
ity of detecting an actively bleeding blood vessel if a
patient is requiring more than 2 units of red blood packed
cells per 4 hours to maintain a hemoglobin > 7 g/dL. The
technical success of angiographic embolisation is above
90%, but prolonged clinical success is less at 65 to 70%.
Early rebleeding will occur in approximately 20 to 30%
of cases. The procedure has a low rate of major compli-
cations. In high-risk patients (APACHE II score > 16)
mortality has been reported to be 23% versus 50% in
patients treated with surgery. Transcatheter arteriography
and intervention is the best treatment method for bleeding
occurring into the biliary tree or pancreatic duct (69-72). 
In the USA the use of surgery to control bleeding has
decreased from 13.1% in 1993 to 9.7% in 2006. There
has also been a significant decrease in the use of defini-
tive surgery (vagotomy or resection). Surgery has a
lower incidence of rebleeding than angiographic emboli-
sation (72). 
In conclusion, angiographic embolisation or surgery
is indicated when arterial bleeding cannot be controlled
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Mallory-Weiss syndrome
Mallory-Weiss syndrome heals spontaneously in
many cases, endoscopic therapy is occasionally neces-
sary. When endoscopic treatment is needed, the same
rules apply as for ulcer bleeding (61). The use of a duo-
denoscope may be very helpful in this setting (5-D).
Tumour
Endoscopic haemostasis for bleeding related to an
UGI tumour is often a temporary measure. Permanent
haemostasis is difficult in many cases due to diffuse
bleeding and the unique solution is surgical resection if
possible (64).
Dieulafoy’s lesion
Bleeding from Dieulafoy’s lesions (mainly located in
the stomach and duodenum) can be controlled by endo-
scopic therapeutic procedures. Hemoclipping is more
effective than injection therapy (65). A safe alternative is
injection plus heater probe coagulation (66). Band liga-
tion was successful in case series but there is a risk of
perforation and delayed bleeding (contraindicated in the
duodenum). Argon plasma coagulation has been used in
a case series (67). Tattooing of the lesion with India Ink
is helpful for locating the lesion in case of endoscopic
retreatment or surgical wedge excision.
PPI continuation or administration after therapeutic
endoscopy
In a large RCT - after therapeutic endoscopy - high-
dose intravenous omeprazole (80 mg bolus IV, followed
by 8 mg/hour for 72 hours) was shown to significantly
decrease the rate of rebleeding by approximately 5 to
10% (35). The need for surgery was reduced non-signif-
icantly by approximately 3%. Mortality was significant-
ly reduced only in patients with active bleeding or non-
bleeding visible vessel. Similar results were obtained
with esomeprazole (after therapeutic endoscopy : 80 mg
bolus IV, followed by 8 mg/hour for 72 hours). An
 updated meta-analysis of RCT’s which included
5792 patients (5), disclosed that PPI therapy after
endoscopy (whether therapeutic or not) dramatically
reduced the rebleeding rate (OR 0,45 CI : 0,36-0,57) and






Spurting bleeding Ia 100%
Oozing bleeding Ib 30%
Non bleeding visible vessel IIa 50%
Adherent clot IIb 30%
Flat spots IIc < 8%
Clean base III < 3%
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with endoscopy. In high risk patients, angiographic
embolisation is preferred over surgery because of lower
mortality (3-C).
Endoscopic treatment for PHT related bleeding
Oesophageal variceal bleeding (Fig. 2)
The diagnosis of an acute variceal bleeding is made
upon the following criteria : active bleeding from a varix
(oozing, spurting) ; presence of a “white nipple” fibrin
clot overlying a varix (signature of variceal rupture) ; a
clot on a varix ; the presence of varices without other
potential source of bleeding and fresh blood in the stom-
ach (12,21,73).
Endoscopic treatment should be performed at the
time of diagnostic endoscopy (within 12 h after admis-
sion) by a skilled endoscopist and should always be used
in association with vasoactive treatment, preferably
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Abbreviations : AB : antibiotic ; EBL : endoscopic band ligation ; TIPSS : transjugular intrahepatic portosystemic shunt.
Fig. 2. — Algorithm for oesophageal variceal bleeding (20, 21, 52) (Baveno V)
08-colle_Opmaak 1  26/01/11  13:46  Pagina 53
54 I. Colle et al.
Endoscopic treatment for gastric variceal bleeding
(Fig. 3)
Fundal varices account for 1-3% of variceal bleeds.
The risk of gastric variceal bleeding is lower than
oesophageal variceal bleeding, however the bleeding is
more severe and mortality is higher (21). There are
 different types of gastric varices as shown in Figure 4. 
Gastro-oesophageal varices type 1 are an extension of
oesophageal varices along the lesser curvature and
should be treated as oesophageal varices (18,52).
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started before endoscopy (1a-A) (18,20). Both sclero -
therapy and endoscopic band ligation (EBL) have shown
to be effective in controlling oesophageal variceal bleed-
ing. The Baveno IV and V guidelines are conclusive in
their advice : endoscopic band ligation is preferred as
this endoscopic therapy for oesophageal variceal bleed-
ing is better for bleeding and rebleeding control and has
less adverse events compared to sclerotherapy.
Sclerotherapy can be accepted if EBL is not feasible,
technically difficult or not available (1b-A) (12,18-
21,23,51,74,75).
Abbreviations : BRTO : Balloon retrograde transvenous obliteration ; PHT : portal hypertension ; TIPSS : transjugular intrahepatic
portosystemic shunt.
Fig. 3. — Algorithm for gastric variceal bleeding (52)
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Endoscopic band ligation or tissue adhesives can be used
(Baveno V) (20).
There are limited data for gastric variceal bleeding
(from isolated gastric varices type 1 and 2 and gastro-
oesophageal varices type 2) but the guidelines are quite
uniform : variceal obliteration with a tissue adhesive
(e.g. N butyl-cyanoacrylate, isobutyl 2 cyanoacrylate) is
recommended and is more effective than EBL or scle-
rotherapy (1b-A) (18,20,51). Obliteration with a tissue
adhesive has a better bleeding and rebleeding control,
should be performed by an expert in endoscopy, can be
difficult during active bleeding and complications
(emboli) can occur (21,52).
If obliteration is not possible, transjugular intra hepat-
ic portosystemic stent shunt (TIPSS) should be consid-
ered (1-B). Tamponade with a Linton balloon can be per-
formed as a bridge to definite therapy (21,52). A Linton
tamponade with 600 mL inflation is more effective than
a Sengstaken Blakemore tamponade (52). 
A second endoscopic attempt to stop gastric variceal
bleeding is not indicated providing glue was used during
the first session (21,52).
Treatment for portal hypertensive gastropathy
Portal hypertensive gastropathy (PHG) is supposed to
cause less than 3% of acute bleedings. There are no RCT’s
assessing treatment for this cause of bleeding. Treatment
is hypothetically based on decreasing gastric blood perfu-
sion with vaso-active agents such as terlipressin or
somatostatin (5-D) (52). Chronic bleeding from PHG can
be treated with beta-blockers or TIPSS (52). Bleeding
from PHT related jejunopathy should also be considered
and assessed by capsule endoscopy (76,77).
Variceal bleeding from non cirrhotic portal hypertension
or extrahepatic portal hypertension
Little literature about the treatment of variceal bleed-
ing from non-cirrhotic portal hypertension is available.
However the same endoscopic therapy for acute bleeding
is advised as in cirrhotic variceal bleeding (2b-B). For
secondary prophylaxis, endoscopic therapy is effective
(2b-B). Decompressive procedures should be considered
for patients with endoscopic failure (5-D) (18,20).
The place of TIPSS and Surgery in PHT related UGIB
(Figure 1 and 2)
WHEN SHOULD COVERED TIPSS BE CONSIDERED ?
Polytetrafluoroethylene (PRFE)-covered TIPSS is
extremely effective in controlling variceal (oesophageal
and gastric) bleeding (control rates approaches 95%) and
has a low risk of obliteration compared to non-covered
stents. The goal of TIPSS placement is to reduce hepatic
venous pressure gradient below 12 mmHg (3a-C) (78).
TIPSS is preferred above surgical shunts (3b-C) (78)
and should be placed by an experienced interventional
radiologist or a specially trained physician (5-D) (20,78).
Sometimes retrograde embolisation of gastric varices
may be required despite adequate decompression of por-
tal venous system (3a-C) (78). TIPSS may decrease liver
function capacity and cause encephalopathy (21). 
EARLY TIPSS PLACEMENT
Two studies from Monescillo (79) and Garcia
Pagan (80) show that high risk patients for rebleeding,
have a survival benefit when early PTFE-covered TIPSS
(within 72 h of admission) is placed compared to stan-
dard therapy (combined vasoactive treatment and band
ligation) (1 year survival of 86% vs. 60%, respectively).
Moreover, early TIPSS had a much lower rate of failure
to control bleeding and of early rebleeding (3%)
 compared to combined vasoactive treatment and band
ligation (50%) (80).
Based on these 2 studies, the recent Baveno V consen-
sus meeting states that early covered TIPSS placement
(within 72 h of admission) should be considered in
patients at high risk for treatment failure. This is in
patients with Child B cirrhosis and active bleeding at
endoscopy and in Child C patients with < 14 points, after
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Fig. 4. — Different types of gastric varices : 
GOV1 : gastro-oesophageal varices type 1 is an extension of oesophageal varices along the lesser curvature
GOV2 : gastro-oesophageal varices type 2 is an extension of oesophageal varices along the fundus
IGV1 : isolated gastric varices in the fundus
IGV2 : isolated gastric varices not in the fundus.
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or death. Failure to control bleeding implies a change in
treatment options. TIPSS is the preferred strategy and
should be placed within 24 hours.
Second-look endoscopy
The definition of a second-look endoscopy (also
called scheduled repeat endoscopy) is an endoscopy
scheduled within 24-72 h after the index bleed, without
any clinical sign of rebleeding. However, the perform-
ance of second-look endoscopy remains controversial. In
the published studies there are important differences in
recruitment criteria, in definitions of recurrent bleeding,
and important heterogeneity in the endoscopic therapies
used, which all contribute to confound the effects of
overall efficacy. In 3 RCT’s either endoscopic injections
or fibrin-glue in second endoscopy was used. Only one
of these studies showed a marginal benefit in the reduc-
tion of recurrent bleeding with second-look endoscopy,
and none showed any benefit on mortality or need for
surgery. In 2 RCT’s (both with small sample size) using
thermal coagulation, a significant reduction in recurrent
bleeding was obtained, but no effect on mortali-
ty (81,82). Most of the beneficial effects of a second-
look endoscopy were published when injection therapy
was used alone and when post endoscopy PPIs were not
used. Therefore, currently, combination of endoscopic
treatments and PPI administration really question the
usefulness of a second look endoscopy (83). Based on
the published data, the panel does not recommend rou-
tine second-look endoscopy, independent of the endo-
scopic technique used to stop the bleeding (1a-A).
However, a clinically meaningful and probably cost-
effective strategy is to select high-risk patients for sec-
ond-look endoscopy and retreatment, especially if the
initial treatment is questionable (5-D). High-risk patients
can be selected on the basis of the Glasgow Blatchford





Rebleeding is defined as clinical evidence of recurrent
bleeding after a successful initial treatment. Risk factors
associated with rebleeding are a past history of peptic
ulcer bleeding, a history of smoking, presentation with
hematemesis, hypovolemic shock before endoscopy,
ulcer size > 2 cm and type of ulcer (84). The GBS and
the Rockall scores are good indicators of rebleeding
(Table 2 and 3). The use of post endoscopy PPIs dramat-
ically reduces the rate of rebleeding from upper gastroin-
testinal lesions (see above).
Re-endoscopy with retreatment is mandatory, inde-
pendently of the endoscopic technique used to stop the
index bleed or the origin of bleeding (1a-A).
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medical and endoscopic treatment is installed (20).
Reserving TIPSS as a rescue therapy after failure allows
the patient sometimes to deteriorate to a point where
 survival is poor. 
TIPSS AS SALVAGE THERAPY :
PTFE-covered TIPSS should be used as a salvage
therapy in the following indications :
– if oesophageal and gastric variceal bleeding is not
controlled with endoscopic and medical therapy
– when oesophageal variceal bleeding recurs despite 2
endoscopic attempts and full medical therapy (1-
C) (12,51) 
– if gastric variceal rebleeding occurs after a single
 failure endoscopy or if obliteration is not avail-
able (12,51,52).
TIPSS FOR OTHER INDICATIONS
TIPSS can also be recommended for recurrent
 bleeding from portal hypertensive gastropathy despite
beta-blockade (4-C) (78). However, TIPSS is not useful
for the treatment of bleeding from gastric antral vascular
ectasia (GAVE) (“water melon stomach”) (78).
SHUNT SURGERY FOR BLEEDING FROM PHT DUE TO INTRA -
HEPATIC DISEASE (CIRRHOSIS MOSTLY)
Shunt surgery is extremely effective in controlling
variceal bleeding (control rates approaches 95%), but
due to worsening of liver function, mortality remains
high. For this reason TIPSS is preferred above surgical
shunts (3b-C) (78).
The ideal patient for surgical therapy is one with well
preserved liver function who fails emergent endoscopic
treatment and has no complications from the bleeding or
endoscopy. The choice of surgery is usually dependent
on the training and expertise of the surgeon.
SHUNT SURGERY FOR BLEEDING FROM PHT DUE TO PORTAL
VEIN THROMBOSIS
Decompressive surgery or interventional radiological
procedures should be considered for patients with
portal vein thrombosis and failure of endoscopic therapy
for bleeding (5-D). (Baveno 5) (20). The Sugiura
 procedure (oesophageal devascularisation) may be
used in patients who are not candidates for a shunt
 operation such as those with extensive portal vein throm-
bosis with  extension into the splenic and superior mesen-
teric veins. 
Mesenteric-left portal vein bypass (“Rex bypass”) is
preferred in managing bleeding from pediatric patients
with chronic extrahepatic portal vein thrombosis, if
 feasible (2b-B) (Baveno V) (20).
Failure to control PHT related bleeding
Definition of failure to control bleeding was defined
in the Baveno guidelines IV and V (18,20) as fresh
hematemesis ≥ 2 hours after the start of a drug treatment
or therapeutic endoscopy ; a 3 g/dL drop in hemoglobin
(≅ 9% hematocrit drop) if no transfusion is administered
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Failure to control non-variceal rebleeding
The same rules apply as for failure during the index
bleed (see above). 
Variceal rebleeding
Definitions
Significant rebleeding is defined by Baveno IV and V
guidelines (18,20) as hematemesis or melena or a
decrease of 3 g/dL hemoglobin if no transfusion is given
after a successful initial treatment after the index
bleed. 
Failure to control bleeding implicates a change in
treatment options.
Endoscopic retreatment and vasoactive medication
(Figure 2 and 3)
If variceal bleeding is mild and the patient is stable, a
second endoscopic therapy might be attempted for
oesophageal varices. For gastric varices only 1 endo-
scopic attempt is allowed. 
If it fails, or when bleeding is severe, the patient
should be offered a derivative treatment (such as TIPSS
described above) (85), before his clinical status further
deteriorates. 
Most patients have already received vasoactive med-
ication for the treatment of the acute variceal bleeding
and to prevent rebleeding. There are no studies showing
that changes in vasoactive medications should be consid-
ered. However, the panel suggests, that increasing the
dose to maximum levels allowed, could be beneficial (5-
D). 
Is there a place for balloon tamponade or oesophageal
covered stents ? See B.14.
BALLOON TAMPONADE
Balloon tamponade is indicated for uncontrolled
bleeding from oesophageal/gastric varices for whom a
definitive therapy is planned within 24 h (1-B) (51). It is
thus mostly used as a bridge to TIPSS or surgery.
Balloon tamponade is effective in bleeding control
(80%) but rebleeding after balloon deflation is high
(50%). Complication rate (aspiration, migration, necro-
sis and perforation of the oesophagus) is high and asso-
ciated with high mortality. The balloon should be
released within 24 h to avoid necrosis of stomach/
oesophagus. Linton tamponade (600 mL) can be used
for oesophageal and gastric varices (52). Sengstaken
Blakemore can only be used for oesophageal varices (5-
D).
OESOPHAGEAL COVERED STENTS
A recent report suggests that oesophageal covered
stents might achieve hemostasis in most patients with
refractory oesophageal variceal bleeding, with the
advantage over tamponade of less severe complications
despite longer periods of treatment (12,20,21,53). RCT
are ongoing. No statement concerning this treatment has
been made during the Baveno V consensus meeting
 suggesting that further evaluation is needed (20). 
This treatment is contra-indicated in case of suspect-
ed or obvious bleeding from gastric varices.
Upper GI bleeding follow up
Follow up of non-variceal bleeding patient
When should the patient be discharged from the ICU to
the ward ?
Patients with an active bleeding or visible vessel can
be safely discharged from the ICU to the ward after
1 day, if the patient is stable with no signs of rebleeding
and if there is no other underlying pathology necessitat-
ing a longer stay in the ICU (5-D) (86). 
When should the patient be discharged home ?
Patients without coexisting acute illnesses or bleeding
disorders with clean-base ulcers can be discharged in the
first day of admission (within 24 hours) (87). Patients
with a Glasgow Blatchford score = 0 may even be
 managed as outpatients with elective endoscopy schedul -
ed (16).
The length of hospital stay is often influenced by
additional factors. As most of the rebleedings occur with-
in 72 hours, 4 days could be an optimal hospital stay for
patients with ulcers Forrest Ia-b or IIa and no other
pathology. Other patients might be discharged after
3 days of hospitalization. Patients with a clean ulcer may
be managed as outpatients (84). 
Long term therapy
PPI TREATMENT
In case of a bleeding peptic ulcer, treatment with an
oral PPI once a day is recommended for 6-8 weeks after
treatment of the initial bleeding and achievement of
hemostasis. Eliminating precipitating factors such as
Helicobacter pylori (HP) and non steroidal anti-inflam-
matory drugs (NSAID's) is very important. Treatment of
HP infection is more effective than anti-secretory thera-
py in preventing recurrent bleeding from peptic ulcers.
Confirmation of infection (tests outside of the bleeding
episode) and of eradication is required after HP treat-
ment. 
In case of concomitant acetyl salicylic acid or NSAID
use, especially in high risk patients or patients with a his-
tory of NSAID-related gastric ulcer bleeding, co-therapy
with a PPI is recommended to prevent ulcer recurrence
on the long-term. In case of gastric ulcer, biopsies must
be obtained to exclude underlying neoplasia.
After determining the cause of bleeding by
endoscopy, specific therapy can be initiated. No studies
are available comparing different dosages and duration
of PPI treatment after endoscopic hemostasis of a bleed-
ing ulcer, but the panel suggests that, if there is no
rebleeding within 24 hours, the patient can be switched
to an oral PPI 40 mg once a day for 1 to 2 months. 
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or minimal encephalopathy (5-D). The patient should
have received a check up with ultrasound, Doppler ultra-
sound of the hepatic vessels and serum alpha fetoprotein
level. 
Secondary prophylaxis for variceal bleeding ?
Combination of beta-blockade with EBL is the
 preferred treatment (I-A) (20).
Non-selective beta-blockers should be given in a
 maximal tolerated dose, until the heart rate is between
50-60 beats per minute (1a-A) (18,20). 
Endoscopic band ligation should be repeated every 1-
2 weeks (inquiry during the Vth Baveno meeting revealed
that most centres performed EBL every 2 to 4 weeks)
until eradication (2 to 4 sessions needed mostly), then
repeat endoscopy 1 to 3 months later, and then every 6 to
12 months (1-C) (12,51). 
The Baveno V (2010) guidelines for secondary
 prophylaxis for variceal bleeding (20) are as follows :
– In patients with cirrhosis
The preferred therapy is beta-blockers + endoscopic
band ligation (1a-A). Hemodynamic response assess-
ment to drug therapy provides  prognostic information
about rebleeding risk and survival. Nitrates in combina-
tion with beta-blockers may improve hemodynamic
response in non responders to beta-blockers alone (5-D). 
– In patients with cirrhosis who are unable or unwill-
ing to be treated with endoscopic band ligation :
Beta-blockers + nitrates may be the preferred option.
– In patients who have contraindications or intoler-
ance for beta-blockers (Baveno V = IV) : 
Band ligation is the preferred treatment for prevention
of rebleeding (5-D) (20).
– In patients who fail endoscopic and pharmacologi-
cal treatment for prevention of rebleeding :
Covered TIPSS is effective and is the preferred
option. Surgical shunts (distal splenorenal shunt or 8 mm
H-graft) are effective for patients with Child A/B cirrho-
sis (2b-B) ; it is an alternative if TIPSS is not available.
Transplantation provides good long-term outcomes in
Child C cirrhosis and should be considered (2b-B).
TIPSS can be used as a bridge to transplantation (4-C). 
– Patients who bled from gastro-oesophageal varices
type 1 (GOV1) :
Can be treated with tissue adhesive, beta-blockers or
band ligation (2b-B).
– In patients who bled from gastro-oesophageal
varices type 2 (GOV2) or isolated varices :
Tissue adhesive (1b-A) or TIPSS (2b-B) are recom-
mended.
– In patients who bled from portal hypertensive
gastro pathy (Baveno IV = V)
Beta-blockers should be used for prevention of recur-
rent bleeding (1b-A)
– In patients in whom beta-blockers are contraindi-
cated or failed and who cannot be managed by non-
shunt therapy :
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ERADICATION OF HP
Documentation of HP is advocated. Histology is pre-
ferred. HP should be eradicated in peptic ulcers showing
positive results for this bacteria (88,89).
Triple therapy (PPI twice a day, clarithromycin
500 mg twice daily and amoxicillin 1000 mg twice
daily for 10-14 days, or PPI twice daily in combination
with clarithromycin 500 mg twice daily and metronida-
zole 500 mg twice daily (penicillin allergic patients)
can be used. Confirmation of HP eradication is re -
quired (88,89).
RESUMPTION OF ANTICOAGULANTS AND ANTIPLATELET DRUGS
Resumption of acetyl salicylic acid with concurrent
PPI is superior to switching to clopidogrel alone for
 prevention of gastrointestinal bleeding in patients with
acetylsalicylic acid-related disease (90). Available
 evidence suggests that treatment with a PPI is a useful
precaution in patients with a recent history of gastro -
intestinal ulceration or bleeding that have to start with
aspirin and/or clopidogrel (91,92). 
Acetylsalicylic acid, as a prophylaxis of thromboem-
bolic events, should be restarted as soon as possible, as
withdrawal is associated with a 3-fold higher risk for
major adverse cardiac events (93). According to the liter-
ature acetylsalicylic acid should be ideally resumed 1 or
2 days after endoscopy. 
Recent studies have shown possible interaction
between PPI’s and clopidogrel. However, concomitant
use of pantoprazole or esomeprazole did not have this
effect and may be appropriate PPI’s to be used in patients
in whom there is a clear indication for clopido-
grel (94,95). Clinical trials have shown that PPI’s in stan-
dard doses significantly reduce the incidence of ulcers
associated with the use of NSAID’s (96). 
Follow up of variceal bleeding patient
When should the patient with variceal bleeding be
 discharged from the ICU to the ward ?
Patients with variceal bleeding should always be
 managed at the ICU until the patient is stable.
The patient can be discharged when he is extubated ;
has a good saturation with less than 5 L/min of oxygen ;
is hemodynamically stable without vasopressors ; has a
stable kidney function and has no signs of ongoing
bleeding (5-D).
When should the patient with variceal bleeding be
 discharged to home ?
The highest risk of rebleeding is within 5 days, so the
patients should receive pharmacological treatment for
5 days (20). Beta-blockade should be started around day
4 to have overlap with the vasoactive medication (target
heart rate is 50-60/min) and when no evidence for acute
variceal bleeding within 24 h exists (5-D). 
The patient should be hemodynamically stable ;
 having a stable kidney function ; no active infections ; no
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TIPSS or surgical shunts should be considered (4-C)
(Baveno IV = V) 
Antibiotic (AB) prophylaxis after hospital discharge for
variceal bleeding
In patients who have a variceal bleeding, AB prophy-
laxis should be started on admission as described above
but should be given short term, mostly 7 days (20).
When there is a confirmed infection (spontaneous bacte-
rial peritonitis excluded) AB’s should be given as usual-
ly until the infection is resolved. 
When there was a spontaneous bacterial peritonitis
present, secondary prophylaxis (oral norfloxacine
400 mg 1/d) should be given life long or until transplan-
tation or until ascites resolves completely.
Long term follow-up of the cirrhotic patient
The cirrhotic patient should be screened for the devel-
opment of hepatocellular carcinoma every 6 months with
ultrasound and determination of serum alpha fetoprotein
level. 
An overview of the general management of non-
variceal and variceal bleeding is proposed in Table 6
and 7.
Children’s specific recommendations for the
management of UGIB
Introduction
UGIB in children is uncommon but potentially life
threatening. Due to its rarity, literature data on pediatric
UGIB are scarce. Only one population based pediatric
survey (in children from 2 months to 16 years of age) is
available which was conducted in France (97).
According to this study, the incidence of UGIB in chil-
dren is 1-2/10,000 per year. The incidence of clinically
significant UGIB in children admitted to the ICU has
been reported to be 0.4-1.6% (98). In the French popula-
tion study, the source of bleeding was an oesophageal
lesion in 40%, a gastric lesion in 38% and varices in 5%.
Upper gastrointestinal endoscopy was normal in
17% (97). In centres specialised in pediatric liver disease
the proportion of variceal bleeding might be higher. The
most frequent cause of life threatening UGIB, however,
is variceal bleeding which in children, in contrast to
adults, most often is related to extrahepatic portal vein
obstruction (EHPVO). 
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Table 6. — Management of NON-variceal bleeding
Level of evidence and
Grade recommendation
General supportive care Resuscitation
– Goal  : MAP > 65 mmHg
and/or SBP > 100 mm/Hg
5 - D
– Volume expander  :
Cristalloids
5 - D
– Vasopressors for persistent hypotension
Noradrenaline
5 - D
– Transfusion of blood products  :
packed red blood cells to reach Hb of 8 g/dL
(9-10 g/dL if coronary or cerebrovascular disease)
1 - B
– Intubation and sedation 
ongoing hematemesis, hemodynamic instability, alteration in mental status
5 - D
– Transfer to ICU if
Glasgow Blatchford bleeding score > 8 or GCS < 8
2 - B
Vasoactive medication Not recommended 1 - B
Proton pump inhibitors (PPI) Indicated BEFORE and AFTER endoscopy (40 mg IV bid or continuous infusion
for 72 h depending on severity)
1 - A 
Antifibrinolytic medication No indication 1a - A
Antimicrobial prophylaxis No indication 5 - D
Coagulation factors FFP and platelets  : no evidence prior to endoscopy





Indicated 1 - A
Endoscopy Indicated within 24 h of admission
Earlier if GBS > 8
1 - A
5 - D
Helicobacter pylori eradication Mandatory 1 - A
08-colle_Opmaak 1  26/01/11  13:46  Pagina 59
60 I. Colle et al.
blood pressure may initially be maintained due to impor-
tant vasoconstriction in hypovolemic children.
Hypotension and delayed capillary refill indicate the
necessity of immediate intervention as these are signs of
severe hypovolaemia (> 25% blood loss) and they pre-
cede collapse (Table 8).
In case of hypovolemic shock we refer to the official
European Pediatric Life Support guidelines for the
 management of hypovolemic shock in children. 
Airway protection is always necessary in case of
hemodynamic instability, neurological deterioration
(agitation, GCS < 8, deterioration of the level of con-
sciousness), respiratory distress and ongoing bleeding. It
is also recommended when dealing with infants, in case
of signs of severe bleeding (> 20% loss of blood
 volume), recurrent vomiting and need for invasive
 procedures (e.g. central venous access, endoscopy).
In a hemodynamically stable child, as in adults, blood
volume reconstitution should be done cautiously and
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As UGIB in children is rare, RCT’s on the manage-
ment of UGIB are lacking. Many treatment strategies are
deducted from the management of UGIB in adults and
similar evidence-based approaches do not exist as it
comes to pediatric UGIB. In the following paragraphs,
some specificities and differences in the approach to
UGIB in children compared to adults will be highlight-
ed. 
General Management
Initial management and resuscitation
The initial treatment focuses on maintenance of the
airway and provision of adequate oxygenation and ven-
tilation followed by cardiovascular resuscitation. The
first step is the immediate differentiation between a
hemodynamically stable child and a child in hypov-
olemic shock. In children age-adjusted tachycardia is the
most sensitive indicator of severe blood loss, whereas
Table 7. — Management of variceal bleeding
Level of evidence and
Grade recommendation
General supportive care Resuscitation
– Goal  : MAP > 65 mmHg
and/or SBP > 100 mm/Hg
5 - D
– Volume expander :
Albumin 5%
5 - D
– Vasopressors for persistent hypotension
Noradrenalin or Terlipressin
5 - D
– Transfusion of blood products  :
packed red blood cells to reach Hb of 8 g/dL
(9-10 g/dL if coronary or cerebrovascular disease)
1 - B
– Intubation and sedation 
ongoing hematemesis, hemodynamic instability, alteration in mental state
5 - D
– Transfer to ICU if
Glasgow Blatchford bleeding score ≥ 8
2 - B
Vasoactive medication Before endoscopy
– Terlipressin
bolus I.V.  : 1 – 2 mg according to weight followed by bolus 1-2 mg/4 h
or continuous infusion 6 mg/day for 48 h then 1 mg/4 h until day 5
– Somatostatin
bolus I.V. (5 min) 250 µg followed by continuous infusion 6 mg/day
(if active bleeding at endoscopy 12 mg/day)
1b - A
Proton pomp inhibitors (PPI) No evidence in variceal bleeding
Antifibrinolytic medication No indication 1a - A
Antimicrobial prophylaxis – After blood, ascites and urine cultures
– Amoxicillin – Clavulanic acid or third generation
cephalosporins or Quinolones according to local resistance -
Maximum 7 days
1a - A
Coagulation factors FFP and platelets  : no evidence prior to endoscopy 5 - D
Overtransfusion of FFP and platelets increase portal pressure and bleeding 2b - B
Platelets transfusion if count < 30,000/mL 5 - D
Endoscopy Timing  : as soon as possible (< 12 hours) 5 - D
TIPSS Early (< 72 h) for patients with Child B and active bleeding at endoscopy or
Child C (< 14 points)
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conservatively to maintain hemodynamic stability but to
avoid overcorrection which can maintain the bleeding.
The amount of blood transfused should be adjusted to the
age and weight of the child aiming for a hemoglobin
(Hb) concentration of 8 g/dL which can be calculated
using the following formula : (target Hb concentration –
observed Hb concentration) × 3 × weight of the child in
kg. 
Cholestatic and/or breastfed infants are at risk for
hemorrhagic disease of the newborn due to vitamin K
deficiency. The latter should always be suspected in
infants presenting with UGIB and prompt administration
of IV vitamin K is required. 
The cause of severe life threatening UGIB in children
is most frequently bleeding from varices but on rare
occasions aorto-oesophageal fistula, Dieulafoy lesion, or
ulcers can also be the cause.
Two major categories of UGIB in children should be
differentiated :
1. Mucosal erosion or ulceration : ask for use of
NSAID (97), abdominal pain, foreign body inges-
tion, vomiting, stress factors.
2. Variceal bleeding : look for any clinical signs of liver
disease or a neonatal history of umbilical catheters.
An extrahepatic portal vein obstruction, however,
often first presents with a severe bleeding episode in
an otherwise perfectly healthy child without any pre-
vious history of note.
Some limited blood tests can be helpful in the differ-
ential diagnosis and the assessment of the severity of the
UGIB : Hb and platelet counts, clotting and liver func-
tion tests.
Hospitalisation
Referral to a tertiary care centre where a multidiscipli-
nary team of pediatric intensivists, pediatric gastroen-
terologists and pediatric surgeons is available is indicat-
ed in the following circumstances : important UGIB with
drop in Hb level, (suspicion of) variceal bleeding and
recurrent bleeding. Since early endoscopy is indicated,
transfer should be organized as soon as possible once the
child has been stabilised. 
Initial medical treatment 
The empiric use of acid-suppressive medication in
children is justified based on the predominance of peptic
causes of UGIB. In children, clear evidence is lacking
(only uncontrolled trials and case reports are available)
regarding a possible superiority of PPI’s compared to
H2-blockers (99).
PPI's : In children most data are available for the old-
est molecule : omeprazole. The clearance of omeprazole
in children is influenced by age with a slower metabo-
lism in infants below 10 days of age, an increased metab-
olism between the age of 1 and 6 year and comparable
metabolism to adults thereafter (40,100,101). Further on,
CYP2C19 activity as well as the presence of systemic
inflammatory response will alter the clearance of
omeprazole (102). The recommended doses of IV
omeprazole vary from 1 mg/kg once daily to 0.5 mg/kg
twice daily to 40 mg/1.73 m² in order to maintain the
gastric pH above 4 (99,103,104). 
H2-blockers : The dose of ranitidine needed to main-
tain pH above 4 in children is age dependent. Preterm
infants need 0.5 mg/kg IV twice daily, whereas term
infants need 1.5 mg/kg IV three times a day and children
need 1.5 mg/kg IV four times a day (105,106).
There are no pediatric data on the duration of IV  acid-
suppressive therapy.
Vaso-active drugs : Based on adult data and because
the use of vaso-active medication has been proven to be
safe in children, it is recommended to use vaso-active
drugs as soon as possible before diagnostic endoscopy in
children suspected of variceal bleeding (107). However,
there is a lack of controlled trials in children. 
In Belgium, in pediatric practice, the most frequently
used vaso-active drug is somatostatin (starting bolus
3.5 µg/kg IV over 5 minutes, followed by
3.5 µg/kg/h) (98). In analogy with adults, based on the




An endoscopy can only be performed in a hemo -
dynamically stable child, under general anesthesia with
size adapted material by an experienced endoscopist.
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Table 8. — Normal vital signs, heart rate (HR), respiratory
rate (RR), systolic and diastolic blood pressure
according to children’s age
Diastolic blood pressure = 0.5 to 0.66 × systolic blood pressure.
AGE HR at rest (/min) RR at rest (/min)
Newborn 120-160 30-60
1-6 months 120-150 30-50
7-12 months 110-140 25-40
1-3 months 90-130 20-30
4-5 years 85-120 20-25
6-12 years 70-100 16-22
13-18 years 60-80 12-18
AGE Systolic blood pressure (mmHg)
Normal Lower limit
0-1 months > 60 50
1-12 months > 80 70
1-10 years 90 + [2 × age in years] 70 + [2 x age in years]
> 10 years 110-130 90
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operating channel of the pediatric scope (2 mm) may
limit the treatment options to Argon plasma coagulation
and injection techniques.
In any case of severe UGIB surgical backup should
be available as the blood volume of a child is only 65-
80 mL/kg.
There are no data on the need for a second look
endoscopy after endoscopic treatment of non-variceal
bleeding in children. As in adults, in selected high risk




Failures of initial therapy with combined pharmaco-
logical and endoscopic approach are best managed by a
second attempt at endoscopic therapy. In case of persist-
ent bleeding, shunt procedures are indicated. 
The experience with TIPSS is limited in children. The
procedure is technically more challenging (particularly
in children with biliary atresia due to periportal fibrosis
and small portal veins) and often considered as a bridge
to transplantation (115). Where possible PTFE covered
stents should be used. 
As extrahepatic PHT is more common in children
than in adults, the majority of these young patients are
good candidates for surgical shunt procedures. When
feasible the meso-Rex shunt is preferred (116-118).
Excellent results with portosystemic shunts have been
described in children especially with the distal splenore-
nal shunt (119).
Recurrent non-variceal bleeding
There are no data on the recurrence rate or risk factors of
non-variceal bleeding in children. As in variceal bleeding
a second attempt at endoscopy combined with pharma-
cological therapy is advised.
Follow up
Follow up after variceal bleeding
Band ligation therapy has been shown to be effective
in children with PHT and may be superior to sclerother-
apy when feasible (120). There are no specific pediatric
recommendations about the frequency of endotherapy in
follow-up and eradication of varices in children.
Therefore we refer to the adult BavenoV guidelines.
The use of β-blockade as either replacement or
 additional therapy for band ligation in children requires
further investigation. In children, there is an important
theoretical concern that, by limiting tachycardia, non-
selective β-blockers may impair tolerance of hypo-
volaemia and worsen the outcome from variceal hemor-
rhage (121). It is likely that post-pubertal teenagers will
respond to β-blockers and bleeding like adults whereas
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Endoscopy in young children is more challenging com-
pared to adults : the endoscope can cause pressure on the
trachea, furthermore ventilation problems due to gastric
dilatation by insufflated air occur more frequently. An
experienced pediatric anaesthetist or pediatric intensivist
is therefore required during the procedure.
Indications for early endoscopy are not standardised.
There are no pediatric studies comparing early
endoscopy with conservative management nor has the
risk of re-bleeding been assessed. Endoscopy in children
seems, however, as safe as in adults when performed by
experienced endoscopists (108). Endoscopy is mandato-
ry when blood transfusion is required or in case of unex-
plained recurrent bleeding (109). Endoscopy should be
carried out as soon as possible in a stable patient (within
12-24 hours, preferably even in a shorter time period).
Immediate endoscopy is indicated in case of early failure
to control bleeding (107).
Endoscopic treatment of varices
Based on adult data, antimicrobial prophylaxis direct-
ed at the intestinal flora (second or third generation
cephalosporins) is recommended in children with
variceal bleeding (107).
Sclerotherapy or EBL are as effective in the control of
acute bleeding in children (107). One RCT in 49 children
with EHPVO demonstrated that band ligation achieved
variceal eradication more quickly with a lower re-bleed-
ing rate and fewer complications compared to sclerother-
apy (110). However, the choice of which type of
endotherapy to use should be determined by local
 expertise and technical considerations (107). A specific
concern regarding EBL of oesophageal varices in small
children is the difficulty to pass the loaded apparatus
through the pharynx and the risk of iatrogenic
oesophageal damage. In small children in whom the
adult multiband ligator does not pass, a small size multi-
band ligator adapted for an 8.5 mm endoscope can be
used.
As in adults, acute gastric variceal bleeding can be
controlled using tissue adhesive (e.g. N-Butyl-
Cyanoacrylate) (111), but carries a small risk of acrylate
dislocation causing (cerebral) thrombosis.
Balloon tamponade is a rarely used rescue therapy in
uncontrolled bleeding in children. Experience is very
limited and it should only be used for less than 24 hours
on a pediatric ICU in experienced hands. In very small
children, Foley urinary catheters or oesophageal balloon
dilators can be used instead of the classic Sengstaken
Blakemore or Linton tube.
Endoscopic treatment of non-variceal bleeding
As in adults, ulcers are the most frequent cause of
non-variceal bleeding. If the size of the child permits the
use of adult material the same techniques can be applied
in children. However, published experience is limited to
case reports (112-114). In case of infants, the narrow
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these concerns apply primarily to infants and younger
children. Age may therefore be an important factor in the
decision to prescribe β-blockers. In most studies, the
dose of the β-blocker is adjusted until the heart rate is
reduced to 75% of its baseline value (120). To achieve
this, most children require a dose between 1 and
2 mg/kg/d. Unfortunately, there are no pediatric data to
describe the splanchnic hemodynamic response to β-
blockade or the optimum dosage schedule which gives
maximum efficacy and minimum risk.
Follow-up after non-variceal bleeding
There are no studies on the duration of PPI treatment
after bleeding. There are some case series investigating
healing of oesophagitis due to gastro-oesophageal reflux
in children. In 80% endoscopic healing is observed after
4 weeks of treatment and in 98% after 102 day (103,
121,122). The wide range of healing time might support
the advice to endoscopically check ulcer healing before
stopping treatment in case of a non-variceal UGIB. 
Due to the high omeprazole clearance in children aged
1 to 6 years, the therapeutic doses needed to obtain heal-
ing vary from 0.7 to 3.5 mg/kg/day (100,122). In case of
the presence of HP infection, triple treatment regimens
containing 2 antibiotics and a PPI, are advised for eradi-
cation (123).
Conclusions 
The current guidelines for the management of UGIB
include recommendations for the diagnostic process,
general supportive care, pharmacological therapy aiming
at bleeding control, specific and endoscopic treatment of
acute bleeding and follow-up for both gastro-duodenal
ulcers and portal hypertension induced bleeding. These
guidelines were made for pediatric and adult patients,
however, for pediatric patients there are more expert
opinion guidelines then EBM based guidelines. 
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